InfaCare’s Stannsoporfin For Jaundice Rebuked By US FDA Panel

 
• By Sue Sutter

Uncertainties about clinical benefit and neurodevelopmental safety drive lopsided recommendation against approval; some advisory committee members say that even FDA’s REMS proposal wouldn't be enough to allow stannsoporfin to come to market without further studies.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers